Why the study?
Vaccine development for African swine fever virus is hampered because the function of many ASFV genes remains unknown, prompting investigation into the previously unreported E111R gene.
Does deletion of the E111R gene in the African swine fever virus affect viral replication and porcine virulence?
Does deletion of the E111R gene in the African swine fever virus affect viral replication and porcine virulence?
Deletion of the E111R gene does not significantly attenuate the lethality or replication ability of ASFV, indicating it is not a suitable primary target for live-attenuated vaccine development.
E111R identification may guide ASFV vaccine antigen selection; leaves open functional validation and in vivo testing.
African swine fever (ASF) is an acute infectious disease of domestic pigs and wild boars caused by the African swine fever virus (ASFV), with up to a 100% case fatality rate. The development of a vaccine for ASFV is hampered by the fact that the function of many genes in the ASFV genome still needs to be discovered. In this study, the previously unreported E111R gene was analyzed and identified as an early-expressed gene that is highly conserved across the different genotypes of ASFV. To further explore the function of the E111R gene, a recombinant strain, SY18ΔE111R, was constructed by deleting the E111R gene of the lethal ASFV SY18 strain. In vitro, the replication kinetics of SY18ΔE111R with deletion of the E111R gene were consistent with those of the parental strain. In vivo, high-dose SY18ΔE111R (105.0 TCID50), administered intramuscularly to pigs, caused the same clinical signs and viremia as the parental strain (102.0 TCID50), with all pigs dying on days 8–11. After being infected with a low dose of SY18ΔE111R (102.0 TCID50) intramuscularly, pigs showed a later onset of disease and 60% mortality, changing from acute to subacute infection. In summary, deletion of the E111R gene has a negligible effect on the lethality of ASFV and does not affect the viruses’ ability to replicate, suggesting that E111R could not be the priority target of ASFV live-attenuated vaccine candidates.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: